Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer

MLA

Geoffrey R. Oxnard, et al. “Delay of Treatment Change after Objective Progression on First-Line Erlotinib in Epidermal Growth Factor Receptor-Mutant Lung Cancer.” Cancer, vol. 121, Apr. 2015, pp. 2570–77. EBSCOhost, https://doi.org/10.1002/cncr.29397.

APA

Geoffrey R. Oxnard, David M. Jackman, Mizuki Nishino, Lecia V. Sequist, Suzanne E. Dahlberg, Bruce E. Johnson, Pasi A. Jänne, & Peter C. Lo. (2015). Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer, 121, 2570–2577. https://doi.org/10.1002/cncr.29397

Chicago

Geoffrey R. Oxnard, David M. Jackman, Mizuki Nishino, Lecia V. Sequist, Suzanne E. Dahlberg, Bruce E. Johnson, Pasi A. Jänne, and Peter C. Lo. 2015. “Delay of Treatment Change after Objective Progression on First-Line Erlotinib in Epidermal Growth Factor Receptor-Mutant Lung Cancer.” Cancer 121 (April): 2570–77. doi:10.1002/cncr.29397.